BCI Companies Are Not Selling a Device. They Are Selling a Decade of Support

When people underwrite a BCI company, they tend to price the thing that is easiest to see. The bill of materials for the implant, the cost of the surgery, the margin on the device itself. That is a reasonable place to start, and it is also the wrong place to stop, because a BCI purchase is not really a single transaction. It is the beginning of a relationship that is supposed to last the rest of a patient's life.

An implant needs firmware updates as the software improves. It needs periodic recalibration as the decoder adapts to a brain that keeps changing. In many cases it eventually needs a battery replacement or a hardware revision, which means another surgery years down the line. It needs a support line that actually answers when something stops working, and it needs a company that still exists to answer it.

None of that shows up cleanly in a unit economics slide, but all of it is part of what the patient is actually buying, whether the company frames it that way or not.

This is not a hypothetical risk. It already happened, in a closely related category. A company that made an implanted device restoring partial vision to blind patients ran into serious financial trouble several years ago, and as it fought to survive, it quietly stopped supporting the technology already implanted in hundreds of people. Patients who had built their daily lives around the device were left with hardware they could not get repaired, could not get explained, and in some cases could not safely get an MRI around, because nobody at the company was left to answer basic clinical questions. The company eventually pivoted toward a different product line entirely, and the people who had trusted the earlier device were mostly on their own.

Nothing about that story is unique to one company or one condition. It is a structural feature of building a business on top of something implanted in a human body. A software company that goes under simply stops charging its customers, who move on to a competitor within a billing cycle. A company that goes under after implanting its hardware in someone's skull leaves that hardware behind, whether or not the business survives to support it.

That asymmetry should change how this category gets evaluated, both by the people funding it and the people building it. A BCI company that looks efficient because it is spending very little on long-term patient support may simply be deferring a cost it has not figured out how to price yet — one that becomes a liability, a regulatory problem, or a reputational crisis the moment the business hits a rough patch.

Where this could be wrong

Regulators and payers are paying closer attention to this exact failure mode than they were even a few years ago, partly because of cases like the one above, and that pressure is starting to translate into requirements around post-market support, transition planning, and sometimes escrowed funding meant to protect patients if a company fails. As the category matures, acquirers may also become more willing to take on legacy support obligations as part of a deal, the way some medical device acquisitions already absorb installed-base service contracts rather than treating them as someone else's problem. If those structures become standard, the orphaned-implant problem may be less of a permanent feature of the category and more of a gap that existed while the industry was still too small for anyone to have built the safety net.

What this means for founders

Worth treating long-term patient support as part of the product, not as a cost to minimize until later. That means pricing the decade of firmware, recalibration, battery replacement, and clinical support into the model from the beginning rather than hoping the implant's unit economics will cover it, being honest with boards and investors about what happens to implanted patients if the company fails or gets acquired, and designing continuity — documentation, transition plans, and the ability for another operator to take over — as a feature rather than a footnote. The companies that get this right may not look the most efficient on a unit economics slide. They may be the ones patients can still rely on ten years after the surgery.

WorldChangers is a BCI startup accelerator — at most 10 early-stage companies per batch. If you're building at the brain-machine boundary, applications for Batch 01 are open.